vs
碧迪（BDX）与福克斯集团（FOXA）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是福克斯集团的1.0倍（$5.3B vs $5.2B），碧迪净利率更高（7.3% vs 4.8%，领先2.5%），福克斯集团同比增速更快（2.0% vs -0.4%），碧迪自由现金流更多（$549.0M vs $-791.0M），过去两年福克斯集团的营收复合增速更高（22.6% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
福克斯集团是美国跨国大众传媒企业，总部位于纽约曼哈顿中城美洲大道1211号，在加州伯班克也设有办公点。公司以威廉·福克斯命名，在特拉华州注册，2019年3月19日从21世纪福克斯分拆而来，承接后者的电视广播、新闻及体育业务，由拉克兰·默多克通过家族信托持有36%投票权实现控股。
BDX vs FOXA — 直观对比
营收规模更大
BDX
是对方的1.0倍
$5.2B
营收增速更快
FOXA
高出2.4%
-0.4%
净利率更高
BDX
高出2.5%
4.8%
自由现金流更多
BDX
多$1.3B
$-791.0M
两年增速更快
FOXA
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $5.2B |
| 净利润 | $382.0M | $247.0M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 6.2% |
| 净利率 | 7.3% | 4.8% |
| 营收同比 | -0.4% | 2.0% |
| 净利润同比 | 24.0% | -36.3% |
| 每股收益（稀释后） | $1.34 | $0.52 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXFOXA
| Q4 25 | $5.3B | $5.2B | ||
| Q3 25 | $5.9B | $3.7B | ||
| Q2 25 | $5.5B | $3.3B | ||
| Q1 25 | $5.3B | $4.4B | ||
| Q4 24 | $5.2B | $5.1B | ||
| Q3 24 | $5.4B | $3.6B | ||
| Q2 24 | $5.0B | $3.1B | ||
| Q1 24 | $5.0B | $3.4B |
净利润BDXFOXA
| Q4 25 | $382.0M | $247.0M | ||
| Q3 25 | $493.0M | $609.0M | ||
| Q2 25 | $574.0M | $719.0M | ||
| Q1 25 | $308.0M | $354.0M | ||
| Q4 24 | $303.0M | $388.0M | ||
| Q3 24 | $400.0M | $832.0M | ||
| Q2 24 | $487.0M | $320.0M | ||
| Q1 24 | $537.0M | $704.0M |
毛利率BDXFOXA
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXFOXA
| Q4 25 | 10.5% | 6.2% | ||
| Q3 25 | 11.8% | 21.4% | ||
| Q2 25 | 16.0% | 29.2% | ||
| Q1 25 | 10.4% | 10.8% | ||
| Q4 24 | 8.8% | 10.1% | ||
| Q3 24 | 11.4% | 31.2% | ||
| Q2 24 | 12.1% | 14.6% | ||
| Q1 24 | 14.5% | 27.9% |
净利率BDXFOXA
| Q4 25 | 7.3% | 4.8% | ||
| Q3 25 | 8.4% | 16.3% | ||
| Q2 25 | 10.4% | 21.9% | ||
| Q1 25 | 5.8% | 8.1% | ||
| Q4 24 | 5.9% | 7.6% | ||
| Q3 24 | 7.4% | 23.3% | ||
| Q2 24 | 9.8% | 10.3% | ||
| Q1 24 | 10.6% | 20.4% |
每股收益（稀释后）BDXFOXA
| Q4 25 | $1.34 | $0.52 | ||
| Q3 25 | $1.71 | $1.32 | ||
| Q2 25 | $2.00 | $1.57 | ||
| Q1 25 | $1.07 | $0.75 | ||
| Q4 24 | $1.04 | $0.81 | ||
| Q3 24 | $1.37 | $1.78 | ||
| Q2 24 | $1.68 | $0.68 | ||
| Q1 24 | $1.85 | $1.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $25.3B | $10.9B |
| 总资产 | $54.8B | $21.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDXFOXA
| Q4 25 | $740.0M | — | ||
| Q3 25 | $641.0M | — | ||
| Q2 25 | $735.0M | — | ||
| Q1 25 | $667.0M | — | ||
| Q4 24 | $711.0M | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $2.3B | — |
总债务BDXFOXA
| Q4 25 | — | — | ||
| Q3 25 | — | $6.6B | ||
| Q2 25 | — | $6.6B | ||
| Q1 25 | — | $7.2B | ||
| Q4 24 | — | $7.2B | ||
| Q3 24 | — | $7.2B | ||
| Q2 24 | — | $7.2B | ||
| Q1 24 | — | $7.2B |
股东权益BDXFOXA
| Q4 25 | $25.3B | $10.9B | ||
| Q3 25 | $25.4B | $12.2B | ||
| Q2 25 | $25.5B | $12.0B | ||
| Q1 25 | $25.2B | $11.5B | ||
| Q4 24 | $25.2B | $11.5B | ||
| Q3 24 | $25.9B | $11.3B | ||
| Q2 24 | $25.9B | $10.7B | ||
| Q1 24 | $25.6B | $10.6B |
总资产BDXFOXA
| Q4 25 | $54.8B | $21.5B | ||
| Q3 25 | $55.3B | $22.8B | ||
| Q2 25 | $54.9B | $23.2B | ||
| Q1 25 | $54.5B | $23.4B | ||
| Q4 24 | $54.7B | $23.0B | ||
| Q3 24 | $57.3B | $22.5B | ||
| Q2 24 | $55.6B | $22.0B | ||
| Q1 24 | $54.2B | $21.7B |
负债/权益比BDXFOXA
| Q4 25 | — | — | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.55× | ||
| Q1 25 | — | 0.62× | ||
| Q4 24 | — | 0.63× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.67× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $-669.0M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $-791.0M |
| 自由现金流率自由现金流/营收 | 10.5% | -15.3% |
| 资本支出强度资本支出/营收 | 2.1% | 2.4% |
| 现金转化率经营现金流/净利润 | 1.72× | -2.71× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $2.3B |
8季度趋势，按日历期对齐
经营现金流BDXFOXA
| Q4 25 | $657.0M | $-669.0M | ||
| Q3 25 | $1.4B | $-130.0M | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $164.0M | $2.0B | ||
| Q4 24 | $693.0M | $-362.0M | ||
| Q3 24 | $1.2B | $158.0M | ||
| Q2 24 | $1.3B | $899.0M | ||
| Q1 24 | $514.0M | $1.5B |
自由现金流BDXFOXA
| Q4 25 | $549.0M | $-791.0M | ||
| Q3 25 | $1.0B | $-234.0M | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $35.0M | $1.9B | ||
| Q4 24 | $588.0M | $-436.0M | ||
| Q3 24 | $882.0M | $94.0M | ||
| Q2 24 | $1.1B | $787.0M | ||
| Q1 24 | $380.0M | $1.4B |
自由现金流率BDXFOXA
| Q4 25 | 10.5% | -15.3% | ||
| Q3 25 | 17.0% | -6.3% | ||
| Q2 25 | 19.0% | 42.4% | ||
| Q1 25 | 0.7% | 44.4% | ||
| Q4 24 | 11.4% | -8.6% | ||
| Q3 24 | 16.2% | 2.6% | ||
| Q2 24 | 22.4% | 25.5% | ||
| Q1 24 | 7.5% | 40.4% |
资本支出强度BDXFOXA
| Q4 25 | 2.1% | 2.4% | ||
| Q3 25 | 6.0% | 2.8% | ||
| Q2 25 | 3.2% | 3.6% | ||
| Q1 25 | 2.4% | 1.7% | ||
| Q4 24 | 2.0% | 1.5% | ||
| Q3 24 | 5.4% | 1.8% | ||
| Q2 24 | 3.6% | 3.6% | ||
| Q1 24 | 2.7% | 2.4% |
现金转化率BDXFOXA
| Q4 25 | 1.72× | -2.71× | ||
| Q3 25 | 2.75× | -0.21× | ||
| Q2 25 | 2.12× | 2.10× | ||
| Q1 25 | 0.53× | 5.69× | ||
| Q4 24 | 2.29× | -0.93× | ||
| Q3 24 | 2.94× | 0.19× | ||
| Q2 24 | 2.66× | 2.81× | ||
| Q1 24 | 0.96× | 2.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
FOXA
| Television Segment | $2.9B | 57% |
| Distribution | $1.2B | 22% |
| Other | $621.0M | 12% |
| Advertising | $491.0M | 9% |
